Related studies have found that AML progression from JAK2-mutant (JAK2-mut) myeloproliferative neoplasms (MPN) (after MPN AML) has a poor prognosis, and the BCL-XL is overexpressed in the cells of patients with JAK2-mut MPN [117]. The gene discussed is BCL2L1; the disease is myeloproliferative disorder.